AbClon Inc (174900) - Total Assets
Based on the latest financial reports, AbClon Inc (174900) holds total assets worth ₩68.43 Billion KRW (≈ $46.38 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore AbClon Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.
AbClon Inc - Total Assets Trend (2015–2025)
This chart illustrates how AbClon Inc's total assets have evolved over time, based on quarterly financial data. See 174900 net assets for net asset value and shareholders' equity analysis.
AbClon Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
AbClon Inc's total assets of ₩68.43 Billion consist of 65.1% current assets and 34.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 55.1% |
| Accounts Receivable | ₩280.26 Million | 0.4% |
| Inventory | ₩186.59 Million | 0.3% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩489.72 Million | 0.7% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how AbClon Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see AbClon Inc (174900) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AbClon Inc's current assets represent 65.1% of total assets in 2025, a decrease from 78.3% in 2015.
- Cash Position: Cash and equivalents constituted 55.1% of total assets in 2025, up from 13.4% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 0.7% of total assets.
AbClon Inc Competitors by Total Assets
Key competitors of AbClon Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
AbClon Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.89 | 0.91 | 2.91 |
| Quick Ratio | 4.87 | 0.89 | 2.91 |
| Cash Ratio | 0.00 | 0.22 | 0.30 |
| Working Capital | ₩34.61 Billion | ₩-810.69 Million | ₩11.05 Billion |
AbClon Inc - Advanced Valuation Insights
This section examines the relationship between AbClon Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.16 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 46.8% |
| Total Assets | ₩70.75 Billion |
| Market Capitalization | $296.40 Million USD |
Valuation Analysis
Below Book Valuation: The market values AbClon Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: AbClon Inc's assets grew by 46.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for AbClon Inc (2015–2025)
The table below shows the annual total assets of AbClon Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩70.75 Billion ≈ $47.94 Million |
+46.83% |
| 2024-12-31 | ₩48.18 Billion ≈ $32.65 Million |
+6.08% |
| 2023-12-31 | ₩45.42 Billion ≈ $30.78 Million |
-15.98% |
| 2022-12-31 | ₩54.06 Billion ≈ $36.64 Million |
+81.24% |
| 2021-12-31 | ₩29.83 Billion ≈ $20.21 Million |
-25.67% |
| 2020-12-31 | ₩40.13 Billion ≈ $27.20 Million |
-14.56% |
| 2019-12-31 | ₩46.97 Billion ≈ $31.83 Million |
+63.63% |
| 2018-12-31 | ₩28.70 Billion ≈ $19.45 Million |
+37.57% |
| 2017-12-31 | ₩20.87 Billion ≈ $14.14 Million |
+30.33% |
| 2016-12-31 | ₩16.01 Billion ≈ $10.85 Million |
-0.97% |
| 2015-12-31 | ₩16.17 Billion ≈ $10.96 Million |
-- |
About AbClon Inc
AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company's products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is… Read more